Status of Quantitative Systems Pharmacology Modeling in the Pharmaceutical Industry: A Consortium Survey of the What, When and How

A primary cause of failures in pharmaceutical research and development (R&D) was attributed to lack of efficacy (Hay et al. 2014), suggesting a lack of understanding in therapeutic targets biology and their relevance to disease progression or modulation. Quantitative systems pharmacology (QSP) has the promise of increasing probability of success in R&D by bridging scientific gaps between disciplines to enable target validation (Sorger et al., 2011). In 2014, a group of pharmaceutical industry representatives of the Simcyp Consortium, along with scientists from Certara, initiated discussions on formation of a QSP consortium, with the objective of developing, validating and sharing pre-competitive QSP models. The idea of an industry sponsored QSP consortium managed by Certara was well received by the Simcyp member companies, and here we present results of a survey conducted recently to assess the QSP landscape in the industry. This survey was conducted among all 33 consortium members, and 21 companies returned the questionnaire, a response rate of around 60%. A poster paper of results was presented at the New York Academy of Sciences Meeting on this topic in May, 2015.